Ancora Advisors’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Ancora Advisors’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-526,000	Closed	-$329K	–	2032
2023 Q1	$329K	Hold	526,000	–	–	0.01%	551
2022 Q4	$413K	Buy	526,000 +29,000	+6%	+$22.8K	0.01%	525
2022 Q3	$355K	Hold	497,000	–	–	0.01%	585
2022 Q2	$313K	Buy	497,000 +120,850	+32%	+$76.1K	0.01%	634
2022 Q1	$262K	Hold	376,150	–	–	0.01%	723
2021 Q4	$263K	Buy	376,150 +375,150	+37,515%	+$262K	0.01%	723
2021 Q3	$1K	Hold	1,000	–	–	﹤0.01%	2198
2021 Q2	$1K	Hold	1,000	–	–	﹤0.01%	1933
2021 Q1	$1K	Buy	+1,000	New	+$1K	﹤0.01%	1718

Other funds holding NWBO

Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

MSAM

Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return

WJWM

Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

LDB

Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

AMG

Advisors Management Group La Crosse, Wisconsin $549M AUM 29.35% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

Bartlett & Co Cincinnati, Ohio $6.16B AUM 20.29% 1-Year Est. Return

Ancora Advisors's NWBO Position: Q2 2023 in Review

Ancora Advisors sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2023, closing a stake of 526,000 shares — an estimated $329K sold.

Ancora Advisors first reported a position in NWBO in Q1 2021 and held it in 9 quarters. The position peaked at $413K in Q4 2022. 11 funds tracked by Wall St. Rank hold NWBO as of Q2 2023.

Ancora Advisors reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2023 after selling out during the quarter.
Ancora Advisors sold 526,000 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2023, an estimated $329K.
Ancora Advisors first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2021 and held it in 9 quarters.
Ancora Advisors's Northwest Biotherapeutics, Inc. Common stock position peaked at $413K in Q4 2022.
11 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2023.

Based on Ancora Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.